C07C59/245

Guerbet alcohols and methods for preparing and using same
09840449 · 2017-12-12 · ·

The invention relates to Guerbet alcohol precursors and Guerbet alcohols, as well as to processes for synthesizing them.

Guerbet alcohols and methods for preparing and using same
09840449 · 2017-12-12 · ·

The invention relates to Guerbet alcohol precursors and Guerbet alcohols, as well as to processes for synthesizing them.

METHODS OF MAKING BEMPEDOIC ACID AND COMPOSITIONS OF THE SAME

The invention provides methods of preparing 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid and methods of making a pharmaceutical material comprising a purified amount of 8-hydroxy-2,2,14, 14-tetramethylpentadecanedioic acid. Also provided are compositions and pharmaceutical materials including a purified amount of 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid as well as methods of treating various diseases and conditions using the compositions and pharmaceutical materials.

METHODS OF MAKING BEMPEDOIC ACID AND COMPOSITIONS OF THE SAME

The invention provides methods of preparing 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid and methods of making a pharmaceutical material comprising a purified amount of 8-hydroxy-2,2,14, 14-tetramethylpentadecanedioic acid. Also provided are compositions and pharmaceutical materials including a purified amount of 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid as well as methods of treating various diseases and conditions using the compositions and pharmaceutical materials.

FORMS AND COMPOSITIONS OF INHIBITORS OF PLASMA KALLIKREIN

The present invention provides solid forms of compound (1) and compositions thereof which are useful as inhibitors of Plasma Kallikrein (pKal) and which exhibit desirable characteristics for the same.

##STR00001##

FORMS AND COMPOSITIONS OF INHIBITORS OF PLASMA KALLIKREIN

The present invention provides solid forms of compound (1) and compositions thereof which are useful as inhibitors of Plasma Kallikrein (pKal) and which exhibit desirable characteristics for the same.

##STR00001##

PRODUCTION OF MALIC ACID
20220048845 · 2022-02-17 ·

A method of production of malic acid includes treating a first intermediate product to form a second intermediate product. The treating includes substantially removing impurities from the first intermediate product to obtain a treated intermediate product by gas stripping the crude maleic anhydride, or subjecting a mixture of one or more of the crude maleic acid, the crude fumaric acid, and the vent gas scrubber solution obtained from a phthalic anhydride production process or a maleic anhydride production process to crystallization, passing an aqueous solution of the treated intermediate product through a carbon column to substantially remove retained impurities to form the second intermediate product, obtaining a feed that includes the second intermediate product, and causing the feed to undergo hydration reaction in a tubular reactor or a continuous stirred tank reactor to produce malic acid.

PRODUCTION OF MALIC ACID
20220048845 · 2022-02-17 ·

A method of production of malic acid includes treating a first intermediate product to form a second intermediate product. The treating includes substantially removing impurities from the first intermediate product to obtain a treated intermediate product by gas stripping the crude maleic anhydride, or subjecting a mixture of one or more of the crude maleic acid, the crude fumaric acid, and the vent gas scrubber solution obtained from a phthalic anhydride production process or a maleic anhydride production process to crystallization, passing an aqueous solution of the treated intermediate product through a carbon column to substantially remove retained impurities to form the second intermediate product, obtaining a feed that includes the second intermediate product, and causing the feed to undergo hydration reaction in a tubular reactor or a continuous stirred tank reactor to produce malic acid.

CRYSTALLINE FORMS OF PARP INHIBITORS

The present disclosure relates to crystalline forms of 4,5,6,7-tetrahydro-11-methoxy-2-[(4-methyl-1-piperazinyl)methyl]-1H-cyclopenta[a]pyrrolo[3,4-c]carbazole-1,3(2H)-dione, including salts forms and free base forms.

CRYSTALLINE FORMS OF PARP INHIBITORS

The present disclosure relates to crystalline forms of 4,5,6,7-tetrahydro-11-methoxy-2-[(4-methyl-1-piperazinyl)methyl]-1H-cyclopenta[a]pyrrolo[3,4-c]carbazole-1,3(2H)-dione, including salts forms and free base forms.